Acutaas Chemicals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+33.0%+40.3%+16.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+107.0%+80.6%+4.8%
+116.3%+82.7%+2.0%
+122.2%+229.3%−41.5%
+119.6%+69.8%−49.0%
+28.1%+41.4%+42.9%
+29.6%+93.3%+15.0%
+146.9%−5.5%+91.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ACUTAAS₹3,148.30

Acutaas Chemicals Ltd.

· Pharma & Health
₹ CrorePeersANURASAETHERBLUEJETCAPLIPOINTCONCORDBIOEMCUREJBCHEPHARMERISMcap ₹25,776 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+16.3+40.3+33.0—
EBITDA Growth—+4.8+80.6+107.0—
EBIT Growth—+2.0+82.7+116.3—
Net Income Growth—-41.5+229.3+122.2—
EPS Growth—-49.0+69.8+119.6—
Total Assets Growth—+42.9+41.4+28.1—
Total Equity Growth—+15.0+93.3+29.6—
Cash from Operations Growth—+91.0-5.5+146.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.